{"id":7604,"date":"2025-12-06T09:30:51","date_gmt":"2025-12-06T08:30:51","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7604"},"modified":"2025-12-07T12:35:42","modified_gmt":"2025-12-07T11:35:42","slug":"phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7604\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll\/","title":{"rendered":"Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,686,629,703,691,690,594,656,781,657,595],"class_list":["post-7604","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bgb-16673","post-tag-btk","post-tag-btk-degrader","post-tag-cdac","post-tag-chimeric-degradation-activation-compound","post-tag-chronic-lymphocytic-leukemia","post-tag-cll","post-tag-cll-sll","post-tag-sll","post-tag-small-lymphocytic-lymphoma","congress_resource_type-oral-presentation","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-bgb-16673"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":243,"prioritization":0,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[704,760,781,594,595,686,629,703,691,690],"visible_tags":[704,656,657,686],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis phase 1 study assessed BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had received multiple prior therapies. Among 66 patients, 86% responded to treatment, including those with high-risk genetic mutations and prior resistance to BTK inhibitors. \u00a0BGB-16673 has a tolerable safety profile. Treatment-emergent adverse events (TEAEs) of any grade occurring in \u226525% of patients were fatigue, contusion\/bruising, diarrhea, and neutropenia. Grade \u22653 TEAEs occurred in 63% of patients. Four patients had TEAEs that led to death (all due to infections), but no deaths were related to treatment. BGB-16673 showed robust and deepening responses, and further studies are ongoing to confirm the potential benefits.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis phase 1 study assessed BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had received multiple prior therapies. Among 66 patients, 86% responded to treatment, including those with high-risk genetic mutations and prior resistance to BTK inhibitors. \u00a0BGB-16673 has a tolerable safety profile. Treatment-emergent adverse events (TEAEs) of any grade occurring in \u226525% of patients were fatigue, contusion\/bruising, diarrhea, and neutropenia. Grade \u22653 TEAEs occurred in 63% of patients. Four patients had TEAEs that led to death (all due to infections), but no deaths were related to treatment. BGB-16673 showed robust and deepening responses, and further studies are ongoing to confirm the potential benefits.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-1-cadance-101-study-btk-degrader-bgb-16673-in-rr-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296994","authors":[7550],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"See the ASH 2025 oral of updated results of BTK degrader BGB-16673 in R\/R CLL\/SLL from the ongoing phase 1 CaDAnCe-101 study by Inhye E. Ahn et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/11\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll.jpg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296994\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-06\",  \r\n  \"keywords\": [\"bgb 16673 clinical trial\", \"btk degrader cll\", \"btk degrader clinical trial\", \"results from phase 1 cadance-101 study\"], \r\n  \"genre\": \"Oral Presentation\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Inhye E. Ahn, MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n       \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"See the ASH 2025 oral of updated results of BTK degrader BGB-16673 in R\/R CLL\/SLL from the ongoing phase 1 CaDAnCe-101 study by Inhye E. Ahn et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-btk-degrader-bgb-16673-in-rr-cll-sll\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7550"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/657"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/656"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/703"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/243"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7604"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}